Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optimized Cord Blood Transplantation
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This optimized double-unit cord blood transplant (CBT) protocol was developed by Memorial Sloan Kettering Cancer Center (MSKCC) as a therapeutic approach for adults with high-risk hematologic malignancies. The protocol utilizes two partially HLA-matched umbilical cord blood units as the active biological component to provide a source of hematopoietic stem cells for immune and hematopoietic reconstitution. It incorporates an intermediate-intensity conditioning regimen consisting of cyclophosphamide, fludarabine, thiotepa, and total body irradiation (TBI), along with graft-versus-host disease (GVHD) prophylaxis using cyclosporine-A and mycophenolate mofetil. Key optimizations of this protocol include prioritizing cord blood unit quality and CD34+ cell dose over stringent HLA-matching, ensuring therapeutic cyclosporine levels by the day of transplant, and utilizing letermovir prophylaxis for CMV-positive patients to mitigate transplant-related mortality and improve progression-free survival.
- Other names
- Optimized double-unit cord blood transplant protocolMSKCC Optimized CBTOptimized Cord Blood Transplant in Hematologic Malignancies
Beyond the preview
Go deeper on Optimized Cord Blood Transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optimized Cord Blood Transplantation.